Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates
Globenewswire·2025-12-04 06:00

Core Insights - Vivoryon Therapeutics N.V. reported advancements in its clinical program for varoglutamstat, particularly in improving kidney function in diabetic patients, and successfully completed a capital raise to support its strategic objectives [2][3][4] Financial Results - Revenues for the nine months ended September 30, 2025, were zero, consistent with the same period in 2024 [10] - Research and development expenses decreased by EUR 8.9 million to EUR 3.7 million compared to EUR 12.6 million in the same period of 2024, primarily due to reduced clinical development costs [11] - General and administrative expenses were EUR 4.0 million, down from EUR 4.9 million in the previous year, attributed to lower personnel costs [12] - The net loss for the nine months ended September 30, 2025, was EUR 7.6 million, compared to EUR 17.1 million for the same period in 2024 [12] - Cash and cash equivalents as of September 30, 2025, were EUR 2.5 million, down from EUR 9.4 million at the end of 2024 [13] Clinical Program Updates - The Phase 2 program for varoglutamstat demonstrated statistically significant and clinically meaningful improvements in kidney function (eGFR) compared to placebo in two independent studies [4] - A new analysis indicated a consistent treatment effect across patients with varying eGFR baseline levels, particularly in those with more impaired kidney function [3][7] - The company plans to initiate a dedicated Phase 2b clinical study in patients with diabetic kidney disease (DKD) stage 3b/4, pending additional funding or partnerships [4][16] Corporate Development - Vivoryon successfully completed a private placement raising EUR 5.1 million, extending its cash runway into Q3 2026 [6][14] - The company is actively exploring additional funding and partnership opportunities to support its DKD program and other development initiatives [16] - A new CFO, Marcus Irsfeld, will succeed Anne Doering, who is stepping down in December 2025 [15]